Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment
NCT00538122 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12
Last updated 2009-01-27
Summary
This study is being done to look at the electrical activity of the heart. This study will help decide whether taking recordings for a 24-hour period gives more useful information than recording it for a few seconds in a doctor's office. The study will compare 24 hour electrocardiogram (ECG) results of patients taking thioridazine (Mellaril) to those of other patients taking different medications that took part in another study.
Conditions
- Schizophrenia
- Schizoaffective Disorder
- Bipolar Disorder
Interventions
- DEVICE
-
24 Holter Monitor Recording
All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc. From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects.
Sponsors & Collaborators
- collaborator INDUSTRY
-
Vanderbilt University
lead OTHER
Principal Investigators
-
Herbert Meltzer, M.D. · Vanderbilt University Medical Center
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-07-31
- Primary Completion
- 2008-07-31
- Completion
- 2008-09-30
Countries
- United States
Study Locations
More Related Trials
-
Coronary Artery Disease in Patients Suffering From Schizophrenia
NCT02885792 ·Status: UNKNOWN ·Phase: NA
-
Ocrelizumab for Psychosis by Autoimmunity
NCT03971487 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
NCT00501163 ·Status: COMPLETED
-
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
NCT05245539 ·Status: COMPLETED ·Phase: PHASE1
-
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
NCT03649581 ·Status: RECRUITING ·Phase: NA
-
Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia
NCT01338298 ·Status: COMPLETED ·Phase: NA
-
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
NCT01606436 ·Status: COMPLETED ·Phase: PHASE1
-
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
NCT03062033 ·Status: UNKNOWN
-
An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions
NCT04851691 ·Status: COMPLETED ·Phase: NA
-
The Risk of Myocardial Infarction in Users of Antipsychotic Agents
NCT01236274 ·Status: UNKNOWN
-
Psychiatric Disorders and Electrophysiological Markers
NCT02329119 ·Status: UNKNOWN ·Phase: NA
-
Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks
NCT00709345 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Biomarkers in First Episode Schizophrenia
NCT02033382 ·Status: COMPLETED
-
Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders
NCT00330226 ·Status: UNKNOWN
-
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
NCT00086593 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
NCT04506905 ·Status: COMPLETED ·Phase: PHASE1
-
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
NCT00202306 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918 ·Status: RECRUITING ·Phase: PHASE2
-
Assessment of Pain During Intramuscular Injection Delay in Adult Psychiatry
NCT04784572 ·Status: RECRUITING ·Phase: NA
-
Neurophysiological Studies in Schizophrenia and Psychiatric Disorders
NCT01384604 ·Status: COMPLETED
-
Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II
NCT00377117 ·Status: COMPLETED
-
Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.
NCT01786369 ·Status: COMPLETED
-
Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
NCT02181803 ·Status: COMPLETED ·Phase: PHASE1
-
The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
NCT00468533 ·Status: UNKNOWN ·Phase: PHASE4
-
Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome
NCT00018837 ·Status: COMPLETED ·Phase: NA